PURPOSE:Left ventricular hypertrophy and diastolic dysfunction (LVDD) remain highly frequent markers of cardiac damage and risk of progression to symptomatic heart failure, especially in resistant hypertension (RHTN). We have previously demonstrated that administration of sildenafil in hypertensive rats improves LVDD, restoring phosphodiesterase type 5 (PDE-5) inhibition in cardiac myocytes. METHODS: We hypothesized that the long-acting PDE-5 inhibitor tadalafil may be clinically useful in improving LVDD in RHTN independently of blood pressure (BP) reduction. A single blinded, placebo-controlled, crossover study enrolled 19 patients with both RHTN and LVDD. Firstly, subjects received tadalafil (20 mg) for 14 days and after a 2-week washout period, they received placebo orally for 14 days. Patients were evaluated by office BP and ambulatory BP monitoring (ABPM), endothelial function (FMD), echocardiography, plasma brain natriuretic peptide (BNP-32), cyclic guanosine monophosphate (cGMP) and nitrite levels. RESULTS: No significant differences were detected in BP measurements. Remarkably, at least four echocardiographic parameters related with diastolic function improved accompanied by decrease in BNP-32 in tadalafil use. Although increasing cGMP, tadalafil did not change endothelial function or nitrites. There were no changes in those parameters after placebo. CONCLUSION: The current findings suggest that tadalafil improves LV relaxation through direct effects PDE-5-mediated in the cardiomyocytes with potential benefit as an adjunct to treat symptomatic subjects with LVDD such as RHTN patients.
RCT Entities:
PURPOSE:Left ventricular hypertrophy and diastolic dysfunction (LVDD) remain highly frequent markers of cardiac damage and risk of progression to symptomatic heart failure, especially in resistant hypertension (RHTN). We have previously demonstrated that administration of sildenafil in hypertensiverats improves LVDD, restoring phosphodiesterase type 5 (PDE-5) inhibition in cardiac myocytes. METHODS: We hypothesized that the long-acting PDE-5 inhibitor tadalafil may be clinically useful in improving LVDD in RHTN independently of blood pressure (BP) reduction. A single blinded, placebo-controlled, crossover study enrolled 19 patients with both RHTN and LVDD. Firstly, subjects received tadalafil (20 mg) for 14 days and after a 2-week washout period, they received placebo orally for 14 days. Patients were evaluated by office BP and ambulatory BP monitoring (ABPM), endothelial function (FMD), echocardiography, plasma brain natriuretic peptide (BNP-32), cyclic guanosine monophosphate (cGMP) and nitrite levels. RESULTS: No significant differences were detected in BP measurements. Remarkably, at least four echocardiographic parameters related with diastolic function improved accompanied by decrease in BNP-32 in tadalafil use. Although increasing cGMP, tadalafil did not change endothelial function or nitrites. There were no changes in those parameters after placebo. CONCLUSION: The current findings suggest that tadalafil improves LV relaxation through direct effects PDE-5-mediated in the cardiomyocytes with potential benefit as an adjunct to treat symptomatic subjects with LVDD such as RHTN patients.
Authors: Alexandre Alessi; Andrea Araújo Brandão; Antonio Coca; Antonio Carlos Cordeiro; Antonio Cordeiro; Armando da Rocha Nogueira; Feitosa Diógenes de Magalhães; Audes Feitosa; Celso Amodeo; Cibele Isaac Saad Rodrigues; Cibele Rodrigues; David A Calhoun; David Calhoun; Eduardo Barbosa Coelho; Eduardo Barbosa; Eduardo Pimenta; Elizabeth Muxfeldt; Fernanda Marciano Consolin-Colombo; Fernanda Consolin-Colombo; Gil Salles; Guido Rosito; Heitor Moreno; Jose Fernando Vilela Martin; Juan Carlos Yugar; Luiz Aparecido Bortolotto; Luiz Bortolotto; Luíz Cesar Nazário Scala; Luís Cesar Nazário Scala; Márcio Gonçalves de Sousa; Márcio de Souza; Marco Antonio Mota Gomes; Marcus Bolivar Malachias; Miguel Gus; Oswaldo Passarelli; Paulo César Veiga Jardim; Paulo Roberto Toscano; Ramiro A Sánchez; Ramiro Sanchez; Roberto Dischinger Miranda; Roberto D Miranda; Rui Póvoa; Weimar Kunz Sebba Barroso Journal: Arq Bras Cardiol Date: 2012-07 Impact factor: 2.000
Authors: André Dejam; Christian J Hunter; Mildred M Pelletier; Lewis L Hsu; Roberto F Machado; Sruti Shiva; Gordon G Power; Malte Kelm; Mark T Gladwin; Alan N Schechter Journal: Blood Date: 2005-03-17 Impact factor: 22.113
Authors: Thiago Quinaglia; Ana Paula C de Faria; Vanessa Fontana; Natália R Barbaro; Andréa R Sabbatini; Jonas T Sertório; Caroline Demacq; José E Tanus-Santos; Heitor Moreno Journal: Eur J Clin Pharmacol Date: 2013-08-21 Impact factor: 2.953
Authors: M Kohno; T Horio; K Yokokawa; K Murakawa; K Yasunari; K Akioka; A Tahara; I Toda; K Takeuchi; N Kurihara Journal: Am J Med Date: 1992-01 Impact factor: 4.965
Authors: Walter J Paulus; Carsten Tschöpe; John E Sanderson; Cesare Rusconi; Frank A Flachskampf; Frank E Rademakers; Paolo Marino; Otto A Smiseth; Gilles De Keulenaer; Adelino F Leite-Moreira; Attila Borbély; István Edes; Martin Louis Handoko; Stephane Heymans; Natalia Pezzali; Burkert Pieske; Kenneth Dickstein; Alan G Fraser; Dirk L Brutsaert Journal: Eur Heart J Date: 2007-04-11 Impact factor: 29.983